Core Points - Zhejiang Securities Regulatory Bureau issued a decision regarding Minsheng Securities for violations during the continuous supervision of Weikang Pharmaceutical's IPO [1] - Minsheng Securities failed to adequately monitor the abnormal delays in construction projects and lacked sufficient verification procedures [1] - The internal controls of the investment banking business were found to be deficient, leading to insufficiently cautious conclusions in the continuous supervision documents for Weikang Pharmaceutical for the year 2023 [1] - The actions of Minsheng Securities violated the Securities Issuance and Listing Sponsorship Business Management Measures [1] - The responsible representatives, Ren Shaozhong and Zhong Desong, were held primarily accountable for the violations [1] - As a result, the Zhejiang Securities Regulatory Bureau decided to issue a warning letter as an administrative regulatory measure [1]
浙江证监局对民生证券出具警示函